FINWIRES · TerminalLIVE
FINWIRES

Optiscan Imaging Says Half of Target Patients Imaged in Human Breast Cancer Imaging Study

By

Optiscan Imaging (ASX:OIL) said 25 of the target 50 patients were imaged in its first in-human breast cancer imaging study at Royal Melbourne Hospital in Victoria, reaching a halfway mark milestone, according to a Thursday Australian bourse filing.

The study is assessing surgical margins in breast cancer patients undergoing lumpectomy procedures using the InVue precision surgery imaging device for in vivo imaging and the InForm digital pathology imaging device for ex vivo imaging, per the filing.

InVue is used intraoperatively in the resection cavity to generate live in vivo images immediately after tumor removal, while InForm is used to analyze the excised tissue.

Clinical readouts of the analyzed cases to date show nine with clear margins, four with narrowly clear margins, and five with involved margins, the company said. There were no reported adverse events related to intravenous sodium fluorescein contrast agent injections.

The study was expanded to a second clinical site to accelerate recruitment.

Related Articles

Asia

AcroMeta's Subscription Deal Collapses as Investor Fails Payment; Shares Up 6%

AcroMeta's (SGX:43F) deal to raise SG$1 million through the subscription of 16.7 million shares with a subscriber named Elisabet, collapsed after the investor failed to make the payment by the deadline, according to a Tuesday bourse filing.Shares of the engineering services company were up nearly 6% in Wednesday trading.The subscriber was expected to remit the amount by May 31. The company is now seeking legal advice over the matter following the breach of the agreement.

SGX:43F
Asia

GrainCorp's Through-The-Cycle Earnings Power Under Doubt Even as Fiscal 2027 EBITDA Estimate Unchanged, Jarden Says

GrainCorp's (ASX:GNC) fiscal 2027 earnings before interest, taxes, depreciation, and amortization (EBITDA) estimate was almost unchanged at around AU$217 million, but there is more skepticism than consensus on the firm's through-the-cycle earnings power, with the fiscal 2028 EBITDA estimate 16% and net profit after tax estimate 39% below consensus, Jarden said in a note on Tuesday.The Australian Bureau of Agricultural and Resource Economics and Sciences' (ABARES) first fiscal 2027 crop estimate east coast winter crop of 23.8 million metric tons is in line with expectations and consistent with an average crop size. If the El Niño phenomenon develops over June and July, creating soft levels of rainfall, then for fiscal 2027 there are downside risks to ABARES' forecast.The canola crop forecast is relevant for GrainCorp's nutrition and energy segment, with Jarden estimating it to account for 48% of the fiscal 2027 EBITDA estimate. ABARES' fiscal 2027 east coast canola crop estimate of 2.2 million metric tons is well below the fiscal 2021 to fiscal 2026 period but is impacted by a weak New South Wales forecast.The investment firm retained its neutral rating and AU$5.40 price target on GrainCorp.GrainCorp's shares gained about 2% in recent Wednesday trade.

ASX:GNC
Asia

Sichuan Road & Bridge Exits Private Equity Fund with Early Lump-Sum Payout

Sichuan Road & Bridge (SHA:600039) subsidiary Road & Bridge Group exited a 111.2-million-yuan private equity fund investment tied to a highway project in Guangxi, China.The fund shares were transferred to Guangxi Jiaosheng, with proceeds collected early as a lump sum of 98.3 million yuan, according to a Tuesday filing with the Shanghai bourse.Shares of the construction company were down 3% in recent trade.

SHA:600039